A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo by Bell, Helen S. et al.
Strathprints Institutional Repository
Bell, Helen S. and Dufès, Christine and O’Prey, Jim and Crighton, Diane and Bergamaschi, Daniele
and Lu, Xin and Schätzlein, Andreas G. and Vousden, Karen H. and Ryan, Kevin M. (2007) A p53-
derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. Journal of Clinical
Investigation, 117 (4). pp. 1008-1018. ISSN 0021-9738
Strathprints is designed to allow users to access the research output of the University of Strathclyde.
Copyright c© and Moral Rights for the papers on this site are retained by the individual authors
and/or other copyright owners. You may not engage in further distribution of the material for any
profitmaking activities or any commercial gain. You may freely distribute both the url (http://
strathprints.strath.ac.uk/) and the content of this paper for research or study, educational, or
not-for-profit purposes without prior permission or charge.
Any correspondence concerning this service should be sent to Strathprints administrator:
mailto:strathprints@strath.ac.uk
http://strathprints.strath.ac.uk/
Research article
1008	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 117	 	 	 Number 4	 	 	 April 2007
A p53-derived apoptotic peptide derepresses 
p73 to cause tumor regression in vivo
Helen S. Bell,1 Christine Dufes,2 Jim O’Prey,1 Diane Crighton,1 Daniele Bergamaschi,3 Xin Lu,3 
Andreas G. Schätzlein,2 Karen H. Vousden,4 and Kevin M. Ryan1
1Tumour Cell Death Laboratory, Beatson Institute for Cancer Research, Glasgow, United Kingdom. 2Centre for Oncology and Applied Pharmacology, University 
of Glasgow, Glasgow, United Kingdom. 3Ludwig Institute for Cancer Research, University College London, London, United Kingdom. 4Tumour Suppression 
Laboratory, Beatson Institute for Cancer Research, Glasgow, United Kingdom.
The	tumor	suppressor	p53	is	a	potent	inducer	of	tumor	cell	death,	and	strategies	exist	to	exploit	p53	for	thera-
peutic	gain.	However,	because	about	half	of	human	cancers	contain	mutant	p53,	application	of	these	strate-
gies	is	restricted.	p53	family	members,	in	particular	p73,	are	in	many	ways	functional	paralogs	of	p53,	but	are	
rarely	mutated	in	cancer.	Methods	for	specific	activation	of	p73,	however,	remain	to	be	elucidated.	We	describe	
here	a	minimal	p53-derived	apoptotic	peptide	that	induced	death	in	multiple	cell	types	regardless	of	p53	sta-
tus.	While	unable	to	activate	gene	expression	directly,	this	peptide	retained	the	capacity	to	bind	iASPP	—	a	
common	negative	regulator	of	p53	family	members.	Concordantly,	in	p53-null	cells,	this	peptide	derepressed	
p73,	causing	p73-mediated	gene	activation	and	death.	Moreover,	systemic	nanoparticle	delivery	of	a	transgene	
expressing	this	peptide	caused	tumor	regression	in	vivo	via	p73.	This	study	therefore	heralds	what	we	believe	
to	be	the	first	strategy	to	directly	and	selectively	activate	p73	therapeutically	and	may	lead	to	the	development	
of	broadly	applicable	agents	for	the	treatment	of	malignant	disease.
Introduction
The p53 tumor suppressor serves to protect against the prolifera-
tion of damaged cells that may otherwise go on to form a tumor 
(1). In response to various forms of cellular stress such as DNA 
damage, hypoxia, and oncogene activation, the levels of p53 accu-
mulate initially at mitochondria and subsequently in the nucleus, 
where p53 mediates its tumor-suppressive effects through target 
gene activation (2). A number of tumor-suppressive consequences 
of p53 activation have been described, but it is the induction of cell-
cycle arrest, during which cellular damage can be repaired, and the 
induction of programmed cell death, which causes the eradication 
of damaged cells, that are considered the most important (3).
The type of response that follows p53 activation depends on a 
number of factors. Importantly, oncogenic transformation can 
cause a switch in the cell’s response to p53 activation from growth 
arrest to programmed cell death (4). As a result, many tumor cells 
are more likely to undergo apoptosis following p53 activation 
than are corresponding normal cells (5), making the p53 pathway 
an excellent target for therapeutic intervention (6). A number of 
strategies have therefore been developed to directly and specifi-
cally target p53 (7, 8). However, the fact that approximately 50% 
of human cancers contain nonfunctional mutant p53 limits the 
application of these agents to specific tumor settings (9).
p63 and p73 are 2 p53-related proteins (10). p73 in particular 
(strictly the “TA” splice variants of p73, but hereafter referred to as 
p73 for simplicity) shares many functional characteristics with p53 
and can induce cell death in multiple cell types (11, 12). However, 
although p73 has been shown to be important for chemosensitiv-
ity in tumor cells (13), in contrast to p53, it is rarely mutated in 
human cancer (14). Therefore, the development of agents that tar-
get p73 may result in therapeutic strategies that are more broadly 
applicable than those targeting p53. In this regard, we describe 
here the elucidation and use of a mechanism to directly activate 
p73 that causes p73-dependent cell death and tumor regression 
in the absence or presence of WT p53. The mechanism centers 
around the identification of a minimal apoptotic peptide from 
p53, which, while unable to directly cause p53 target gene acti-
vation, retains the ability to bind iASPP — a common inhibitor 
of p53 family proteins. By binding iASPP, this peptide disrupts 
the interaction between iASPP and p73 causing derepression of 
endogenous p73. This subsequently causes activation of p73 target 
genes and death. In line with these in vitro studies, administration 
of a transgene expressing this peptide in vivo caused tumor regres-
sion in a manner dependent on p73.
Results
A p53-derived 37-aa peptide induces cell death in multiple tumor cell types, 
but not in normal cells. A number of reports have indicated that p53 
can induce programmed cell death through transactivation-inde-
pendent mechanisms. We were intrigued by these studies, as their 
further investigation could potentially lead to novel and tractable 
ways of inducing selective cell death for therapeutic gain. One 
report in particular showed that a construct expressing only the 
first 214 aa from mouse p53 (termed dl214) could induce apop-
tosis without the activation of p53 target genes (15). We decided 
to investigate whether a similar truncation of human p53 would 
function in an analogous manner (Figure 1A). We began by 
expressing the first 210 aa from WT human p53 in p53-null Saos-
2 cells in order to rule out effects of endogenous p53, but this did 
not induce programmed cell death despite successful transfection 
(data not shown). Subsequent Western blot analysis demonstrat-
ed, however, that this truncation was not expressed at detectable 
levels (data not shown). In order to stabilize this truncation and 
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for ease of detection, we fused the 210-aa domain to GFP. This cre-
ated a fusion protein (referred to here as tr210) that not only was 
effectively expressed when transiently transfected into Saos-2 cells 
(Figure 1B), but also resulted in accumulation of cells with sub-G1 
content (Figure 1C), a verified measure of apoptotic rate (16). Cell 
death also occurred when a construct expressing WT p53 fused to 
GFP (referred to here as wtp53) was transfected into Saos-2 cells. 
Conversely, no death was observed following expression of a GFP 
fusion protein containing the first 105 aa from p53 (referred to 
here as tr105), even though this protein was expressed at a level 
higher than that of tr210 (Figure 1, B and C), which indicates that 
the death seen from tr210 was not caused solely by overexpression 
of a GFP fusion protein. Concordantly, removal of GFP from tr210 
and tr105 and subsequent fusion of the truncations to a portion of 
the luciferase gene gave similar results, indicating that cell death 
was dependent on the first 210 aa of p53 and not on the genera-
tion of the GFP fusion in tr210 (data not shown).
Since fusion to GFP resulted in stable proteins, we were able 
to refine the apoptotic region of tr210. We found that in order 
to retain its full apoptotic potential, tr210 could only be refined 
N-terminally to the beginning of the second evolutionarily con-
served box of p53 (aa 118; data not shown). From the C terminus, 
refinement could only extend to the end of the third evolutionarily 
conserved box (aa 171; data not shown). Because these 2 evolution-
arily conserved boxes are juxtaposed in the crystal structure of the 
p53 core domain (17), we tested whether the intervening sequence 
between the boxes could be removed without affecting the abil-
ity of the peptide to induce cell death. Indeed, when expressed 
in Saos-2, this peptide — composed of only 37 aa and referred to 
herein as 37AA (Figure 1A) — resulted in induction of cell death 
comparable to that observed for tr210 (Figure 1C). No cell death 
was seen, however, when either conserved box II or conserved box 
III was expressed independently (data not shown). The amount of 
cell death from 37AA increased with time (Figure 1D); however, 
Figure 1
The p53-derived peptide 37AA induces cell death without direct activation of p53 target genes. (A) Representation of the p53 mutants used in 
this study. Full-length p53 is shown in green with 5 evolutionarily conserved regions (boxes) shown in yellow. Two truncations, tr105 (aa 1–105) 
and tr210 (aa 1–210), are shown as well as the composition of the 37AA peptide, with aa from conserved box II (residues 118–142) in red and 
those from conserved box III (residues 171–181) in blue. (B–E) Cells were transiently transfected with the indicated plasmids and subsequently 
analyzed 36 hours (C and E) and 48 hours later (D) for changes in cell cycle and cell death by flow cytometry. Ap, apoptosis. (B) Cells were 
transiently transfected with the indicated plasmids, and transgene expression was determined by Western blotting. The additional lower band 
seen following expression of 37AA represents expression from an alternate internal methionine. Mutation of this methionine to alanine resulted 
in expression of the larger protein species only and produced identical results (not shown). (F) No direct activation of p53 target genes by 37AA 
was observed. Saos-2 cells were transfected with luciferase reporter plasmids for the p53 target genes p21, Bax, and PIG3 as well as with the 
indicated expression constructs. After 24 hours, cells were assayed for luciferase activity, and the data were normalized against transfected β-gal 
activity. Values represent fold activation relative to activity of GFP alone, which was assigned as 1.
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similar to the original mouse dl214 truncation (15), but different 
from wtp53, this increase in cell death was not accompanied by 
changes in cell-cycle status (Figure 1E).
We next sought to determine whether 37AA is defective in trans-
activation, as was found with the mouse dl214 truncation (15). We 
performed luciferase reporter assays, which measure direct trans-
activation potential, with constructs containing p53-responsive 
promoter fragments from the p21 gene and from proapoptotic 
p53 target genes Bax and PIG3. In line with previous reports using 
these reporter constructs (18–20), wtp53 effectively transactivated 
the reporter in each case. However, 37AA was essentially inert in 
this assay, showing luciferase activity similar to that of cells trans-
fected with GFP alone (Figure 1F). This result was identical to that 
previously reported with the mouse truncation dl214 (15) and 
indicates that 37AA induces cell death despite lacking the ability 
to directly transactivate p53 target genes.
We next tested whether the death-inducing activity of 37AA was 
specific to Saos-2 cells, or whether 37AA could kill other tumor 
cell lines. We expressed 37AA along with wtp53, tr210, and tr105 
in 2 cell types that differ from Saos-2 in different ways: LoVo cells, 
which are derived from a colonic adenocarcinoma and contain 
WT p53; and HeLa cells, which are cervical in origin and also 
contain WT p53. The p53 in HeLa, however, is rendered essen-
tially null due to the presence of high-risk human papilloma virus 
(HPV), with the E6 protein of this virus causing p53 degradation 
(21). In both LoVo and HeLa cells, similar to our results in Saos-2 
cells, 37AA caused apoptosis, as determined by the appearance of 
cells with sub-G1 DNA content, whereas minimal death was seen 
with tr105 (Figure 2, A and B). Interestingly, in the cases of Saos-2 
and LoVo (Figure 1, C and D, and Figure 2B), the amount of death 
seen with 37AA was less than that seen with wtp53. In contrast, 
37AA caused more death in HeLa cells than did wtp53 (Figure 
2D). This presumably reflects the fact that wtp53 was degraded 
by the HPV-E6 protein, but 37AA was not (data not shown). Con-
cordantly, although wtp53 expression was detected on longer 
exposures of the immunoblot (data not shown), the difference 
in expression of wtp53 and 37AA in HeLa cells was much greater 
than in the other cell lines analyzed (Figure 1B and Figure 2, C 
Figure 2
37AA causes selective killing of tumor 
cells. Tumor cell lines LoVo (A and B) 
and HeLa (C and D) as well as primary 
cell cultures MEF (E and F), HFF (G and 
H), and RPE (I and J) were transfected 
or infected with the indicated transgenes. 
After 48 hours (transfection, A–D) or 
72 hours (infection, E–K), transgene 
expression was assessed by West-
ern blotting (A, C, E, G, and I), and the 
effects on cell death were determined by 
flow cytometry (B, D, F, H, J, and K).
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and D). Taken together, these data indicate that in some contexts 
37AA can be a better inducer of death than WT p53.
Previous studies have shown that p53 shows selectivity in its 
ability to kill tumor cells, with many primary untransformed cells 
being relatively resistant to the apoptotic effects of p53 (4, 22). We 
therefore tested whether the same was true for 37AA. Since the nor-
mal patient-derived counterparts of the tumor cell lines analyzed 
do not exist, we used freshly prepared mouse embryo fibroblasts 
(MEFs) as well as 2 primary human cell cultures, human foreskin 
fibroblasts (HFFs) and retinal pigment epithelial cells (RPEs), 
that had been immortalized with telomere reverse transcriptase. 
Because these cells are all difficult to transfect, they were instead 
infected with adenoviruses expressing GFP, tr105, wtp53, tr210, 
and 37AA. As shown in Figure 2, E–J, although each of the trans-
genes was effectively expressed, very little cell death was detected in 
these cells following introduction of either 37AA or wtp53. These 
adenoviruses, however, induced cell death in Saos-2 and LoVo cells 
at levels similar to those following transient transfection (data not 
shown). These data therefore indicate that 37AA shows selectivity 
for tumor cell killing. To test this further, we used RPEs infected 
with the potent oncogene E1a. These cells, as well as parental RPEs, 
were then infected with tr105 and 37AA. E1a caused the cells to 
Figure 3
37AA binds to iASPP and disrupts its interaction with p73. (A) 37AA binds iASPP. Saos-2 cells were infected with adenoviruses expressing GFP, 
wtp53, tr105, tr210, and 37AA following transfection with Flag-iASPP. Cells were lysed and split into 2 and used for either Western analysis (GFP 
blot) or IP (Flag-iASPP pulldown and GFP blot). WB, Western blot. (B) 37AA does not affect iASPP protein levels. Cells were transfected with 
iASPP and either GFP, 37AA, or empty vector. Protein levels were measured by Western blotting. (C and D) 37AA affects iASPP localization 
and dissociates iASPP from p73. Cells were transfected with iASPP, GFP, 37AA, or p73. (C) iASPP and GFP localization was determined by 
immunofluorescence. (D) iASPP binding to p73 was determined by IP.
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become markedly more sensitive to cell death induction by 37AA, 
indicating a selectivity in 37AA for killing oncogene-transformed 
cells (Figure 2K). In comparison, no sensitization to cell death was 
seen with tr105 (Figure 2K), despite its clearly detectable expres-
sion (data not shown).
tr210 and 37AA kill cells via inhibitory member of the ASPP family bind-
ing and p73. Because 37AA is composed of only 37 aa, it seems most 
conceivable that this molecule induces death through a protein-
protein interaction. Before searching for a binding protein through 
which 37AA mediates its effects, we first considered the plethora 
of proteins that have already been shown to bind p53. Above all, 
it was believed that not only must the binding protein bind in the 
region from which 37AA is derived, but since p53 can induce apop-
tosis in a wide range of tissues, the binding protein should also 
be ubiquitously expressed. Moreover, since our analysis of subcel-
lular localization indicated that 37AA most likely functions in the 
nucleus (data not shown) and not in the cytoplasm or mitochon-
dria, as has been proposed for other transactivation-independent 
cell mechanisms of p53, we considered that the binding protein 
through which 37AA induces death may also be a nuclear protein. 
One protein that fulfils these criteria is the apoptosis stimulat-
ing protein of p53 (ASPP) family member inhibitory member of 
the ASPP family (iASPP) (23). ASPP proteins have previously been 
shown to act as both positive (i.e., ASPP1 and ASPP2) and nega-
tive (i.e., iASPP) regulators of p53-induced apoptotic death (24, 
25). Although ASPP1 and ASPP2 are predominantly cytoplasmic 
(26, 27), iASPP exists in both the cytoplasm and the nucleus (23), 
and we therefore hypothesized that if 37AA could bind this anti-
apoptotic member of the family, it may act to sequester iASPP 
and thereby permit death. We generated a FLAG-tagged form of 
iASPP and expressed this in cells together with 37AA and the other 
GFP fusion constructs previously described. Cell lysates were then 
subjected to IP with anti-FLAG antibody and analyzed by Western 
blotting for GFP. Not only was 37AA immunoprecipitated with 
iASPP, but so were wtp53 and tr210 (Figure 3A). No binding was 
seen, however, with the tr105 truncation, indicating that only the 
fusion proteins that induce cell death were immunoprecipitated in 
this assay for iASPP binding.
Although 37AA clearly bound iASPP, a previously described neg-
ative regulator of p53, we found in the present study that 37AA 
induced cell death in cells null for p53 (Figure 1B). However, ASPP 
proteins have also been shown previously to regulate cell death 
downstream of p53 family members p63 and p73 (24). We there-
fore considered whether 37AA, by binding iASPP, may result in 
derepression of p53 family members and thereby cause death. We 
began by testing whether 37AA could affect iASPP protein lev-
els or iASPP localization such that downregulation of iASPP or 
relocalization of iASPP would diminish its antiapoptotic effects. 
While 37AA had no effect on the stability of iASPP (Figure 3B), it 
seemed to cause a partial relocalization of iASPP from the nucleus 
Figure 4
Expression of iASPP or interference with 
p73 inhibits 37AA-mediated cell death. (A) 
Saos-2 cells were transfected with the indi-
cated plasmids and then infected with an 
adenovirus (Ad) expressing ΔN-p73α or 
empty virus control (Con). After 48 hours, 
cells were analyzed for cell death by flow 
cytometry or for expression of transfected 
plasmids by Western blotting. (B) Saos-2 
cells that had been infected with a retrovirus 
expressing either an shRNA directed against 
TA-p73 (pRS-p73) or a scrambled control 
(pRS-Scr) were transfected with the indicat-
ed plasmids. After 48 hours, cells were ana-
lyzed for cell death by flow cytometry or for 
expression of transfected plasmids by West-
ern blotting. (C) Saos-2 cells were transiently 
cotransfected with the indicated amounts of 
37AA and iASPP. After 48 hours, cells were 
analyzed for cell death by flow cytometry 
and for expression of transfected plasmids 
by Western blotting. (D) The effects of 
iASPP knockdown by RNA interference in 
p53-null cells were determined. Saos-2 cells 
were transfected with plasmids expressing 
2 different shRNAs that target iASPP or a 
scrambled shRNA control. The effects of 
the shRNAs on transfected iASPP expres-
sion were determined by Western blotting 
after 24 hours, and the effects on long-term 
survival were determined by assessing the 
clonogenic capacity of the cells. G418 con, 
control for drug activity; cells were mock-
transfected and selected with G418. Original 
magnification, ×1. 
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to the cytoplasm (Figure 3C). As a result, we reasoned that by bind-
ing iASPP, 37AA may be disrupting the interaction of iASPP with 
p53 family members. Coimmunoprecipitation experiments were 
undertaken to test this using 37AA, iASPP, and p73. In the pres-
ence of GFP, p73 was clearly detected following IP of iASPP (Figure 
3D). However, this was greatly reduced in cells cotransfected with 
37AA (Figure 3D). As no changes in the input levels of iASPP or 
p73 were observed, these data indicate that the iASPP-p73 com-
plex can be disrupted by 37AA and raises the possibility that 37AA 
induces death through derepression of p53 family members.
To test for the involvement of p53 family members in 37AA-
induced death, we used a naturally occurring form of p73α lacking 
a transactivation domain, ΔN-p73α. Previous studies have shown 
that ΔN-p73α has the capacity to inhibit the activity of various 
transcript variants of TA-p73 as well as transactivation-competent 
forms of p63 (TA-p63) and p53, and is therefore a broad-spectrum 
inhibitor of the p53 family (28). Indeed, expression of ΔN-p73α 
reduced the amount of cell death observed following expression 
of 37AA (Figure 4A). In the absence of ΔN-p73α, 37AA induced 
apoptosis at a rate of about 25%–30% when expressed for 48 hours. 
When 37AA was coexpressed with ΔN-p73α, however, apoptosis 
was reduced to basically background levels (less than 5%). As would 
be expected, in line with a previous study suggesting essential 
roles for p63 and p73 in p53-induced death (29), a similar effect 
of ΔN-p73α was also seen following coexpression with p53, with 
apoptosis again being reduced to background levels (Figure 4A). 
Because the effects on cell death are pleiotropic in these experi-
ments, this does raise the question of whether ΔN-p73α inhibits 
37AA-induced death in a specific manner, or whether ΔN-p73α 
is simply a broad suppressor of programmed cell death. The fact 
that no effect of ΔN-p73α expression was seen during Bax-induced 
death, however, indicates that this suggests the latter is not the 
case (data not shown).
As ΔN-p73α can inhibit the effects of both TA-p63 and TA-p73, 
our results with this construct do not discern whether 37AA-
induced cell death is mediated by p63, by p73, or by both equally. 
Because p73 has a more documented role in cell death and che-
mosensitivity (13), we decided to analyze more directly the role of 
p73 in 37AA-induced death. We used a previously described RNA 
interference construct designed to specifically knock down TA 
variants of p73 (30). Saos-2 cells were retrovirally infected with this 
construct (pRS-p73) or with a construct expressing a scrambled 
short hairpin RNA (shRNA construct; pRS-Scr). Subsequent trans-
fection of these cells with 37AA revealed that while cells infected 
Figure 5
37AA does not transactivate directly, but causes secondary activation through p73. (A) Saos-2 cells were transiently transfected with 5 μg PUMA 
luciferase plasmid and 200 ng each of the indicated expression constructs. After 72 hours, cells were assayed for luciferase activity, and the data 
were normalized against transfected β-gal activity. Values represent fold activation relative to the activity of GFP alone, which was assigned as 1. 
(B) Saos-2 cells were infected as indicated with adenoviruses expressing tr105, 37AA, ΔN-p73 adenovirus, or control empty adenovirus. At 
the indicated time points, RNA was isolated from the cells and subjected to RT-PCR for PUMA and GAPDH. (C) At the same time cells were 
harvested and assessed for changes in cell death by flow cytometry. (D) Cells were infected with the indicated adenoviruses for 48 hours. The 
mRNA levels for PUMA, DR5, Bax, and p21 were determined by qPCR. Samples were normalized to the levels of 18S ribosomal RNA. (E) 
Schematic of the mode of action of 37AA. Introduction of 37AA into p53-null cells sequesters iASPP and thereby derepresses p73. TA-p73 sub-
sequently activates apoptotic target genes such as PUMA to bring about programmed cell death. In line with this model, cell death from 37AA 
can be inhibited by decreasing p73 activity or increasing iASPP.
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with the scrambled shRNA died in a manner similar to that of 
parental Saos-2 cells (see Figure 1B), those infected with pRS-p73 
were completely resistant to death from 37AA, with levels of apop-
tosis comparable to those of tr105 or GFP alone (Figure 4B). These 
data essentially parallel the results obtained with ΔN-p73α and 
therefore clearly show that in these cells, 37AA induces death by a 
mechanism dependent on TA-p73.
If our hypothesis was correct that 37AA was serving to seques-
ter iASPP away from p73, cell death should also be inhibited by 
increasing the levels of iASPP. To test this, constant levels of 37AA 
were expressed in Saos-2 cells together with increasing amounts 
of iASPP. Following transfection, cells were harvested and ana-
lyzed for cell death by flow cytometry. Excess exogenous iASPP 
indeed inhibited cell death induced by 37AA (Figure 4C). When 
expressed alone, 37AA (3 μg) induced approximately 30% apop-
tosis following expression for 48 hours. This was reduced to 12% 
when 37AA was coexpressed with 6 μg iASPP. Conversely, if the 
cell death seen was solely due to iASPP sequestration and there 
were no other signals from 37AA, cell death should also be evident 
as a result of iASPP depletion. We therefore generated shRNA con-
structs to knock down iASPP. These shRNA constructs caused a 
marked reduction in the amount of iASPP protein expressed from 
an iASPP expression vector when compared with the effects of 
a scrambled shRNA control (Figure 4D). Transient transfection 
of these constructs into Saos-2 cells, however, did not result in 
detectable cell death in the short term, as assessed by flow cytome-
try — presumably due to the long half-life of the endogenous pool 
of iASPP protein (data not shown). However, when expressed con-
tinually over a period of 2 weeks to allow for depletion of endoge-
nous iASPP, these constructs caused a considerable decrease in the 
clonogenic potential of the cells compared with cells transfected 
with scrambled shRNA control (Figure 4D). Consistent with our 
observations using 37AA, these results confirm that perturbing 
the function — or in this case, the levels — of iASPP can result in a 
decrease in the viability of p53-null cells.
37AA causes transactivation via p73. Although our previous analy-
sis of the transactivation capacity of 37AA indicated it could not 
activate p53 target genes directly (Figure 2), we considered that 
the removal of iASPP from p73 may result in secondary gene acti-
vation via p73. This secondary activation may not be evident in 
luciferase reporter assays, as they generally measure the activity of 
an excess of transfected expression plasmid on an excess of trans-
fected reporter plasmid. The possibility of transactivation occur-
ring via a relatively small amount of a cellular intermediary (p73) 
is therefore unlikely. We reasoned that if secondary activation was 
occurring during 37AA-induced death, we may be able to detect 
it by examining endogenous target gene activation — an excess 
of transfected 37AA could activate a relatively small amount of 
cellular p73, which could then have the capacity to activate the 
cellular promoter. To test this possibility, we analyzed activation 
of p53 upregulated modulator of apoptosis (PUMA), a target gene of 
both p53 and p73 (31–33), in p53-null H1299 cells, which are 
known to induce p73 in response to treatment with cisplatin (34). 
While treatment with cisplatin caused a p73-dependent induc-
tion of endogenous PUMA, this was not reflected in activation 
of a transfected PUMA luciferase construct, which was present 
in comparatively vast excess in the cells (Supplemental Figures 
1 and 2; supplemental material available online with this arti-
cle; doi:10.1172/JCI29820DS1). Further analysis of this PUMA 
reporter indicated, as was seen with our analysis of other target 
genes (Figure 2), that the reporter was strongly activated by wtp53 
but not by 37AA (Figure 5A). However, infection of Saos-2 cells 
with an adenovirus expressing 37AA resulted in strong activation 
of endogenous PUMA, whereas no activation was seen with tr105 
(Figure 5B). This induction of PUMA occurred concomitantly 
with the ability of 37AA to induce cell death (Figure 5C), and, as 
with 37AA-induced death, dominant-negative ΔN-p73 abolished 
the induction of PUMA, indicating that this indeed represents a 
secondary activation via p73 (Figure 5B). As a result, we tested 
whether other previously described p73 target genes are activated 
by 37AA and also whether this activation could be deleted after 
adenoviral administration at a time point that just precedes 
death (48 hours). Since the level of activation of target genes at 
this time point may be below the threshold required for detec-
tion by semiquantitative RT-PCR, mRNA levels were analyzed by 
quantitative real-time PCR (qPCR). Not only was activation of 
PUMA evident at this time point, but mRNA for death receptor 5 
(DR5; ref. 35) was also induced (Figure 5D). The induction levels 
Figure 6
37AA causes tumor regression in vivo. 
Cultures of LoVo (A), LoVo-E6 (B), LoVo-
E6–pRS-Scr (C), LoVo-E6–pRS-p73 
(D), and LoVo-E6–iASPP cells (E) were 
injected into the flanks of athymic mice. 
Upon tumor formation (day 0), mice were 
treated by intravenous tail vein injection 
on days 0, 2, 4, 6, and 8 with DNA-den-
drimer complexes containing 50 μg of 
37AA, wtp53, or tr105. Tumor volume was 
measured daily, and growth was plotted 
as relative to tumor size on day 0.
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were similar to those following infection of cells with TA-p73 or 
following treatment with cisplatin — an agent known to activate 
endogenous p73 (Supplemental Figure 2; ref. 34). Moreover, con-
sistent with a role for p73 in 37AA action, activation of both of 
these targets was greatly impeded when cells were infected with 
dominant-negative ΔN-p73 (Figure 5D). However, we saw no acti-
vation of Bax (another proapoptotic target of p53 and p73; Figure 
5D), indicating that 37AA-induced, p73-mediated gene activation 
may be selective for certain target genes. However, the extent to 
which WT p53 and TA-p73 can activate Bax needs to be deter-
mined before any conclusions can be drawn about the regulation 
of Bax in these cells.
In addition to analysis of the activation of apoptotic target genes, 
we also analyzed the activation of the cell-cycle regulator p21. As 
ASPP proteins are considered to selectively regulate activation of 
apoptotic genes, we were surprised to observe that 37AA caused 
activation of p21 (Figure 5D). This activation was not dependent 
on p73, however, and the nature of this induction — whether 
mechanistically linked to 37AA, possibly through a p73-indepen-
dent mechanism, or simply a response to 37AA action — therefore 
remains unclear. The induction of p21 by 37AA also seems to be 
inconsistent with the fact that 37AA did not affect cell-cycle pro-
gression (Figure 1E). Analysis of p21 protein levels revealed that 
this change in p21 mRNA was not reflected in changes in p21 
protein (data not shown), proving an explanation for this appar-
ent paradox. Taken together, therefore, our data suggest a model 
wherein p53-null cells, 37AA binds to iASPP, resulting in the dere-
pression of p73. Therefore, even in the absence of other signals, 
p73 is free to activate apoptotic target genes such as PUMA and 
DR5 to invoke programmed cell death (Figure 5E).
37AA causes tumor regression in vivo. Since 37AA can cause cell 
death in multiple tumor cells types in vitro, we next questioned 
whether 37AA would work as a therapeutic agent in vivo to cause 
selective cell death and tumor regression. As Saos-2 cells are non-
tumorigenic in athymic mice, we decided to analyze the effects 
of 37AA on tumors formed with LoVo cells, which are frequently 
used in xenograft studies. Cultures of LoVo cells were therefore 
injected into the flanks of mice to induce tumor formation. Once 
tumors were palpable, mice were treated by intravenous injection 
of 37AA, wtp53, or tr105 expression plasmids using a nanoparticle 
nonviral delivery system involving complexes of DNA with poly-
propylenimine dendrimers. This system has been developed by us 
and by others and has been shown to deliver highly tumor-spe-
cific expression of a transgene and, where a death-inducing gene is 
used, tumor regression with limited toxicity (36, 37). Moreover, our 
present studies showed that tail vein injection of DNA-dendrimer 
complexes containing CMV-driven β-gal can induce transgene 
expression within the tumor comparable to that seen following 
intratumoral injection (Supplemental Figure 3). When coupled 
with the ability of this systemically delivered agent to potentially 
treat disseminated disease, this makes this approach an exciting 
prospect for nonviral anticancer gene medicine.
Animals bearing tumors were therefore treated on days 0, 2, 4, 
6, and 8 relative to the day of tumor palpability with dendrimers 
containing 50 μg of wtp53, tr105 or 37AA. Analysis of tumor size 
during these treatments revealed that while tumors treated with 
tr105 exhibited transgene delivery and yet continued to grow 
(Figure 6A and Supplemental Figure 4), tumor growth in mice 
treated with wtp53 and 37AA was greatly impeded, with marked 
tumor regression occurring in both cases (Figure 6A). The effects 
of DNA-dendrimer complexes on animal body weight were mini-
mal and similar following all treatments (Supplemental Figure 5). 
Since LoVo cells contain endogenous WT p53, we next sought to 
determine whether the effects of 37AA on tumor regression were 
dependent on p53. To inactivate p53, therefore, LoVo cells were 
infected with a retrovirus expressing HPV-E6, which causes the 
degradation of p53 (21) but not p73 (38). These cells were then 
injected into mice and treated with DNA-dendrimer complexes as 
before. As shown in Figure 6B, 37AA was still very effective against 
tumors formed from LoVo-E6. In contrast, due to the presence of 
E6 (and consistent with what we observed in vitro in HeLa cells; 
Figure 1D), the effectiveness of dendrimers containing wtp53 was 
greatly compromised compared with that in WT LoVo cells (Fig-
ure 6, A and B). This demonstrates not only that 37AA is able to 
cause tumor regression in the presence and absence of endogenous 
p53, but also that, in terms of gene therapy, it seems to be effective 
in situations where the therapeutic potential of delivering WT p53 
would be greatly compromised.
We next considered whether, in the absence of p53, 37AA was 
causing therapeutic effects in vivo that could be affected by modu-
lating the levels of p73 and iASPP. To do this, we generated a LoVo-
E6 cell line that expresses the TA-p73–targeting shRNA construct 
we had used in our in vitro studies. When compared to tumors 
generated with LoVo-E6 cells containing a scrambled shRNA as 
control (LoVo-E6–pRS-Scr), those generated with the shRNA to 
target TA-p73 (LoVo-E6–pRS-p73) were markedly resistant to 
the therapeutic effects of 37AA (Figure 6, C and D). This loss of 
therapeutic response was also evident in cells that had been engi-
neered to overexpress iASPP (LoVo-E6–iASPP), with tumor growth 
in 37AA-treated mice essentially identical to that of mice treated 
with tr105 (Figure 6E). Taken together, these results are consis-
tent with the view that the therapeutic effects of 37AA occur by a 
mechanism in line with the model we established based on our in 
vitro results (Figure 5E).
Discussion
To our knowledge, this study represents the first report of a mech-
anism to directly target p53 family members for therapeutic gain. 
We have demonstrated that expression of the 37AA hybrid peptide 
from p53 was capable of inducing apoptosis of cultured cells in 
vitro regardless of p53 status and, concordantly, that nanoparticle 
delivery of this peptide causes tumor regression in vivo by a mech-
anism dependent on p73. Human tumors exhibit a very low fre-
quency of p73 mutation, and consequently 37AA or its functional 
mimetics may have a broad therapeutic role for the treatment of 
malignant disease, although it must be considered that not all 
tumors will express p73. Functional molecular analysis revealed 
that 37AA acts via sequestration of iASPP, and we have previously 
shown that iASPP functions as a negative regulator of p53, p73, 
and possibly p63 (39). Sequestration or inhibition of iASPP may 
therefore have even broader therapeutic value. For example, in 
situations where p73 is absent, it would be predicted that interfer-
ence with iASPP binding or function may well induce cell death 
by p53, p63, or both, if they are present. Moreover, when all p53 
family members are present, one might predict an even stronger 
cell death response.
A number of recent reports have indicated that iASPP is 
overexpressed in breast cancers and certain leukemias (39, 40). It 
seems possible that in these cases, iASPP overexpression may be 
involved in both the establishment and the maintenance of tumors. 
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In terms of therapy, this could therefore be extremely important 
if, as we predict, iASPP serves to suppress signals that promote 
cell death. In this regard, although p73 was not analyzed in these 
studies, it is noteworthy that increased iASPP expression in breast 
cancer exhibited significant reciprocity with mutation of p53 (39). 
Therefore, in these tumors, iASPP may be acting in an enhanced 
manner to inhibit p53-mediated cell death responses, thereby cir-
cumventing the pressure to mutate p53 directly. In the leukemia 
study, there was no evident relationship to p53 status, indicating 
that iASPP overexpression may promote leukemogenesis by a mech-
anism that does not involve p53 inactivation, and it is tempting to 
speculate that this may involve inactivation of p73. Either way, we 
predict that if the establishment and maintenance of these tumors 
is intrinsically dependent on iASPP, this may widen the therapeutic 
window of iASPP inhibition and indicate that these tumors would 
be hypersensitive to the effects of 37AA or its mimetics.
Finally, it is worthy to consider how 37AA or other subsequently 
derived agents that perturb iASPP function may work in conjunc-
tion with chemotherapeutic agents that are currently in the clinic. 
It is clear from our present results that dendrimer-delivered 37AA 
cannot cause complete tumor regression and that tumors regrow 
with time (Figure 6). Although dendrimer administration is very 
tumor specific, only about 25% of the tumor cells expressed the 
transgene following each administration (Supplemental Figure 4). 
Therefore, there is clearly room for the improvement of dendrimer 
technology in general. In terms of this study specifically, it is partic-
ularly notable that a number of drugs have previously been shown 
to increase the levels of p73, and p73 has been shown to be impor-
tant for chemosensitivity in response to these drugs (13, 41, 42). It 
is not known, however, whether these agents disturb the interaction 
of p73 with iASPP, although our initial observations indicated that 
37AA did not affect the levels of p73 (data not shown). It therefore 
remains possible that interference of iASPP in combination with 
these drugs may result in an enhanced therapeutic response.
As with any rationally designed, molecularly targeted therapy, 
profiling of tumors will always be a prerequisite to determining 
the likely effectiveness of this strategy, which we believe to be 
novel, in any given tumor. For example, tumors overexpressing 
ΔN-forms of p73 that lack a transactivation domain could poten-
tially be resistant to iASPP perturbation (28). However, in light of 
the provocative observations presented here, there appears to be 
clear value in the further investigation of 37AA or its derivatives as 
agents for cancer therapy.
Methods
Plasmids. The plasmids EGFP-N1wtp53, EGFP-N1tr105, EGFP-N1tr210, 
and EGFP-N137AA were made by inserting wtp53, tr105 (residues 1–105 
from wtp53), tr210 (residues 1–210 from wtp53), and 37AA (fusion of 
residues 117–142 and 171–181 from wtp53) fragments into pEGFP-N1 
(Clontech) using EcoRI and BamHI restriction sites. pcDNA3V5iASPP 
has been described previously (43). Flag-iASPP (RAI splice variant) was 
cloned into PCB6+ from cDNA with primers containing an N-terminal 
FLAG tag and KpnI and NotI restriction sites. An EcoRI/EcoRV fragment 
from this plasmid containing the FLAG-iASPP insert was then cloned 
into pLPC to generate pLPC-iASPP. pShuttleCMV-GFP, pShuttleCMV-
p53, pShuttleCMV-tr105, pShuttleCMV-tr210, and pShuttleCMV-37AA 
were made by inserting GFP, wtp53, tr105, tr210, and 37AA fragments 
into pShuttleCMV (Stratagene) using BglII and NotI restriction sites. 
pShuttleCMV–HA–TA-p73α and pShuttleCMV–HA–ΔN-p73α were 
created by cloning HA–TA-p73α and HA–ΔN-p73α fragments from 
pcDNA3-HA vectors (kindly donated by T. Crook, Breakthrough Breast 
Cancer, London, United Kingdom) into the pShuttleCMV vector using 
KpnI and XhoI restriction enzymes. EGFP-N1–PUMA has been described 
previously (31). The reporter constructs for PIG3 and p21 and PUMA 
were kindly provided by B. Vogelstein (Howard Hughes Medical Insti-
tute and Johns Hopkins University, Baltimore, Maryland, USA) and have 
been described previously (18, 19, 32). The reporter construct for Bax 
was kindly provided by J. Reed (Burnham Institute for Medical Research, 
La Jolla, California, USA) and has also been described previously (20). 
pJ3Ωβ-gal has been previously described (16). pWZLBlast-E6 was gen-
erated by PCR amplification of E6 sequences to include a 5' FLAG tag 
and BamHI restriction sites. Amplified sequences were cloned into the 
BamHI site of pWZLBlast.
Cell culture, transfection, and retroviral infection. Saos-2, Saos-2–pRS-Scr, 
Saos-2–pRS-p73, HeLa, H1299, MEF, HFF, RPE, RPE-E1a, LoVo, LoVo-E6, 
LOVO-E6–iASPP, LoVo-E6–pRS-Scr, and LoVo-E6–pRS-p73 cells were 
grown in DMEM supplemented with 10% fetal bovine serum and main-
tained at 37°C in an atmosphere of air and 5% CO2. All cells except 
Saos-2–pRS-Scr, Saos-2–pRS-p73, RPE-E1a, LoVo-E6, LoVo-E6–iASPP, 
LoVo-E6–pRS-Scr, and LoVo-E6–pRS-p73 were obtained from ATCC. 
For tumor-tracking purposes, all LoVo lines expressed GFP. MEFs were 
isolated from day E13.5 C57BL/6 mouse embryos using standard tech-
niques. Saos-2–pRS-Scr, Saos-2–pRS-p73, and LoVo-E6 cells were gener-
ated by infection with pRetroSUPER-Scr (pRS-Scr), pRetroSUPER-p73 
(pRS-p73) (Oligoengine), and pWZLBlast-E6, respectively. Secondary 
infections of LoVo-E6 with pLPC-iASPP, pRS-Scr, and pRS-p73 were per-
formed to generate the lines LOVO-E6–iASPP, LoVo-E6–pRS-Scr, and 
LoVo-E6–pRS-p73, respectively. Retroviruses were generated by transfec-
tion of Phoenix packaging cells (G. Nolan, Stanford University, Stanford, 
California, USA). Infective supernatants were then administered to target 
cells followed by appropriate drug selection as previously described (44). 
Calcium phosphate precipitation was used to transiently transfect cells 
as previously described (16). Cells were harvested at the times indicated in 
the legends to Figure 1, B–F, Figure 2, A–D, Figure 4, A and B, and Figure 
5A. For cell death and luciferase assays, cells were respectively plated prior 
to transfection at 0.8 × 106 and 0.5 × 106 cells per 9-cm dish. Assays were 
conducted as previously described (16).
Western blotting and IP. Cells were lysed in a RIPA buffer, and protein was 
quantified using a BCA assay (Sigma-Aldrich). For each IP, 1,000 μg pro-
tein lysate was used; for Western blot, 50 μg protein was used per lane. The 
antibodies used were as follows: HA-tagged anti-rabbit polyclonal antibody 
(Upstate USA Inc.), FLAG-tagged anti-M2 monoclonal antibody (Sigma-
Aldrich), anti-V5 (Invitrogen) and anti–GFP full-length Aequorea victoria 
peptide polyclonal antibody (BD Biosciences). For IP, iASPP was transiently 
transfected into Saos-2 cells. Where indicated in Figure 2, A, B, and D, cells 
were cotransfected with or infected respectively with plasmids and adeno-
viruses expressing p73 or p53-GFP fusions. For adenoviral infections, cells 
were washed 3 times in serum free medium and adenoviruses were added at a 
concentration of 12 infectious units per cell for 12 hours. FLAG-tagged anti-
M1 agarose affinity gel was used for precipitating FLAG-tagged protein.
Generation of adenoviruses. Linearized Shuttle plasmids were electropor-
ated into BJ5183-AD-1 electrocompetent cells (Stratagene) containing the 
Adeasy-1 adenoviral construct. Recombinant plasmids were then amplified 
in XL10-Gold cells (Stratagene) and transfected into HEK293 cells after 
restriction digest with PacI. Following infectious adenovirus amplification 
in HEK293 cells, purified virus was isolated by freeze-thaw extraction and 
titered using the BD Biosciences Adeno-X Rapid Titer kit. Adenoviruses 
were added to cultures at a concentration of 12 infectious units per cell.
RT-PCR and qPCR. RT-PCRs for PUMA were performed using the QIAGEN 
Proofstart PCR kit with Q-solution and 1 μl proofstart DNA polymerase per 
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reaction. The primers used were 5'-GCTGGCGGAGCAGCACCTGGAGT-3' 
 (forward) and 5'-GGCTCTGTGGCCCCTGGGTAA-3' (reverse). These pro-
duce a fragment of 287 bp. The PCRs were run for 28 cycles at annealing 
temperature of 62°C and 1-minute extension cycle. RT-PCRs for GAPDH 
were performed using the PCR core kit (Applied Biosystems). The primers 
used were 5'-ACCACAGTCCATGCCATCAC-3' (forward) and 5'-TCCAC-
CACCCTGTTGCTGTA-3' (reverse). These produce a fragment of 580 bp. 
The PCRs were run for 21 cycles at annealing temperature of 66°C and 
1-minute extension cycle. qPCR analysis was carried using the DyNAmo 
SYBR Green 2-step qRT-PCR kit (Finnzymes). Validated QuantiTect primer 
sets for p21, PUMA, DR5, Bax, and 18S ribosomal RNA (QIAGEN) were 
used. Data collection was carried out using a Chromo4 real-time PCR detec-
tor and analyzed with Opticon Monitor 3. qPCR cycling parameters were 
15 minutes at 95°C; 34 cycles of 10 seconds at 94°C, 30 seconds at 55°C, 
and 30 seconds at 72°C; and 10 minutes at 72°C. Expression levels of genes 
analyzed by qPCR were normalized to 18S ribosomal RNA levels.
RNA interference and cell viability assays. iASPP shRNA target sequences 
were determined using the Oligoengine online design tool. One scram-
bled/random sequence was also designed. The chosen sequences were 
iASPP shRNA1-ACAGTACCAGCAGATCATC, iASPP shRNA2-CTACTC-
TATCGTGGATTTC, and a random shRNA-ACTGATCTGCATGTATT-
GG–. DNA oligos were then designed with the appropriate hairpin and 
restriction sites added. The DNA oligos were annealed and cloned into 
the pRetroSUPER-neo-GFP vector following manufacturers instructions. 
Following sequencing, the effectiveness of the constructs to knockdown 
iASPP was determined by transient cotransfection of each shRNA with 
FLAG-iASPP. iASPP levels were then determined by Western blotting after 
24 hours. To test the effects of iASPP depletion on cell viability, 1 × 106 
Saos-2 cells were plated and subsequently transfected with 10 μg of each of 
the pRetroSUPER iASPP shRNA vectors or the pRetroSUPER scrambled 
vector. Forty-eight hours after washing, the cells were trypsinized and split 
into 150-mm-diameter plates containing 600 μg/ml G418. The plates were 
cultured for 4 weeks with twice-weekly medium changes containing G418. 
The plates were then washed with 10% methanol, and the colonies were 
visualized using a Giemsa stain according to the manufacturer’s instruc-
tions (Sigma-Aldrich). pRetroSUPER-p73 was kindly provided by K. 
Sabapathy (National Cancer Centre, Singapore). A corresponding plasmid 
containing a scrambled sequence was generated as outlined above.
Immunofluorescence. Saos-2 cells were transiently transfected with 
pcDNA3, pcDNA3V5-iASPP, EGFP-N1, and/or 37AA. Twenty-four hours 
after transfection, cells were fixed in 4% paraformaldehyde and permea-
bilized with 0.3% Triton. Nuclei were stained with DAPI, and iASPP was 
detected using a rabbit V5 antibody (Invitrogen) and anti-rabbit Texas red 
secondary antibody (Molecular Probes).
Animals and xenograft studies. Female CD-1 nude mice (mean initial weight, 
25 g) were housed in groups of 5 at 19°C to 23°C with a 12-hour light/ 
12-hour dark cycle. They had free access to food and water. Experimental 
work was carried out in accordance with UK Home Office regulations and 
approved by the local Ethical Review Panel at the University of Glasgow. 
Cell suspensions of 106 exponentially growing cells were injected in each 
flank. Tumors (typically 6 mm in diameter) were palpable 6 days after 
subcutaneous injection. Gene therapy treatments were administered by 
intravenous tail vein injection on the day tumors became apparent (day 0) 
and on days 2, 4, 6, and 8 as previously described (36). These treatments 
consisted of nanoparticles of polypropylenimine dendrimer (generation 3, 
PPIG3, DAB-Am16) and plasmid DNA (5:1 w/w, 50 μg DNA) encoding 
either 37AA, tr105, or wtp53. Free PPIG3 dendrimer was also administered 
systemically. Control mice were injected with the plasmid DNAs or received 
no treatment. Animals (n = 6) were weighed daily, and their tumor volume 
(determined from caliper measurements and calculated as d3 × π/6, where 
d represents diameter) was recorded.
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